No abstract

No abstract

Objective: The aim of this study was to evaluate the association of tenascin-C (TnC) and total oxidant-antioxidant status to rheumatic or congenital heart valve diseases (HVD) in pediatric patients. Methods: Fifty pediatric patients (25 rheumatic HVD patients and 25 congenital HVD patients) and 20 healthy age-matched control subjects, aged 3-17 years, were enrolled in this observational and cross-sectional study. Serum total antioxidant capacity (TAC), total oxidant status (TOS), oxidative stress index (OSI) and TnC levels were compared among the groups. ANOVA and Kruskal-Wallis tests were used for statistical analysis. Results: Serum TnC level of the patients with rheumatic HVD [median 9.09 (0.94-46.30) ng/mL] was significantly higher than both congenital HVD and control groups [median 2.97 (0.66-11.80) ng/mL; p<0.01, 4.72±1.77 ng/mL; p<0.05, respectively]. However, there was no statistically significant difference between the congenital and control groups in terms of serum TnC level. The levels of serum TAC, TOS and OSI were found to be statistically similar in all groups. In addition, there were no correlations between the level of TnC, and TOS and OSI. Conclusion: Tenascin-C can be used as a biochemical marker in the differential diagnosis of rheumatic and congenital HVD. As the oxidant and antioxidant systems were found to be in equilibrium in rheumatic and congenital HVD, oxidative stress can be thought not to have a marked role in the etiopathogenesis of rheumatic HVD during childhood. (Anadolu Kardiyol Derg 2013; 13: 350-6) Key words: Children, rheumatic valve disease, congenital valve disease, tenascin-C, total antioxidant capacity, total oxidant status Original Investigation Özgün Araşt›rma 350ÖZET Amaç: Bu çalışmanın amacı çocukluk döneminde romatizmal veya konjenital kapak hastalıklarının serum tenascin-C (TnC) ve total oksidan-antioksidan seviyeleri ile ilişkisini değerlendirmektir. Yöntemler: Yaşları 3-17 arasındaki 50 çocuk hasta (25 romatizmal kapak hastası, 25 konjenital kapak hastası) ile yaşça uyumlu 20 sağlıklı birey bu enine kesitli ve gözlemsel çalışmaya alındı. Tenascin-C, total anti-oksidan kapasite (TAC), total oksidan seviye (TOS) ve oksidatif stres indeks (OSİ) değerleri gruplar arasında karşılaştırıldı. Gruplar arası karşılaştırmalarda ANOVA ve Kruskal-Wallis testi kullanıldı. Bulgular: Romatizmal kalp hastalığı grubunun TnC düzeyleri [ortanca 9.09 (0.94-46.30) ng/mL] konjenital ve kontrol gruplarından yüksek bulundu [sırasıyla ortanca 2.97 (0.66-11.80) ng/mL, p<0.01; 4.72±1.77 ng/mL, p<0.05]. Ancak konjenital grup ile kontrol grubunun TnC düzeyleri arasında istatistiksel olarak anlamlı bir farklılık saptanmadı. Gruplar arasında TAC, TOS ve OSI değerleri açısından da farklılık saptanmadı. Tenascin-C düzeyi ile TOS ve OSI arasında da korelasyon saptanmadı. Sonuç: Tenascin-C, romatizmal kapak hastalıkları ile konjenital kapak hastalıkları ayırıcı tanısında bir biyokimyasal marker olarak kullanılabilir. Romatizmal ve konjenital kapak hastalıklarında oksidan ve antioksidan sisteml...

The present study shows that increased serum IMA levels in patients with ARF at the time of diagnosis is a sign of increased inflammation. Thus, serum IMA levels may be used as a follow-up marker like CRP and ESR for evaluating the efficacy of treatment in ARF.

This study aimed to investigate homogeneity disorders of ventricular repolarization and atrial conduction via QT dispersion and P-wave dispersion in children with congenital heart disease (CHD) and pulmonary arterial hypertension (PAH). Three groups of 20 each were generated and involved in this study. The first group included 20 children with both CHD and PAH. The second group consisted of 20 children with CHD but no PAH, and the third group was composed of 20 age- and sex-matched healthy children. Electrocardiographic records were used to determine P-wave, QT, and corrected QT (QTc) dispersions. The pulmonary hypertension group compared with the group having no pulmonary hypertension and the control group showed a significantly longer P-wave dispersion duration (39.10 ± 9.54 vs. 26.30 ± 4.99 ms, p < 0.001; and 24.80 ± 6.94 ms, p < 0.001, respectively) and QT dispersion duration (52.80 ± 15.11 vs. 37.60 ± 6.00 ms, p < 0.001; and 35.00 ± 7.77 ms, p < 0.001, respectively). In addition, the durations of maximum QTc and QTc dispersion were significantly longer in pulmonary hypertension group than in the other two groups. The risk of atrial and ventricular arrhythmia was found to be increased in the patients with both CHD and PAH. Physicians should pay close attention to possible atrial and ventricular arrhythmias during the treatment and follow-up evaluation of these patients.